Francisco Alarcon Aguilar

Dr. Francisco Alarcon Aguilar

Universidad Autónoma Metropolitana, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1995 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
RRR. Roman-Ramos
R. Roman-Ramos
JFJ.L. Flores-Saenz
J.L. Flores-Saenz
FAFrancisco Alarcon Aguilar
Francisco Alarcon Aguilar

1 October 2007 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FAFrancisco Alarcon Aguilar
Francisco Alarcon Aguilar
AZAlejandro Zamilpa
Alejandro Zamilpa
MPMa. Dolores Perez-Garcia
Ma. Dolores Perez-Garcia
Julio C Almanza-PerezJulio C Almanza-Perez
Julio C Almanza-Perez
EREunice Romero-Nuñez
Eunice Romero-Nuñez
RRRuben Roman-Ramos
Ruben Roman-Ramos

1 July 2016 in Physiology & Behavior
Verified
Journal Article
Closed access
ALAna Laura López-López
Ana Laura López-López
HJHerlinda Bonilla Jaime
Herlinda Bonilla Jaime
MVMaría del Carmen Escobar Villanueva
María del Carmen Escobar Villanueva
MPMalinalli Brianza Padilla
Malinalli Brianza Padilla
GPGonzalo Vázquez Palacios
Gonzalo Vázquez Palacios
FAFrancisco Alarcon Aguilar
Francisco Alarcon Aguilar

1 December 2008 in European Journal of Pharmacology
Verified
Journal Article
Closed access
FAFrancisco Alarcon Aguilar
Francisco Alarcon Aguilar
Julio C Almanza-PerezJulio C Almanza-Perez
Julio C Almanza-Perez
GBGerardo Blancas
Gerardo Blancas
SASelene Angeles
Selene Angeles
RGRebeca Garcia-Macedo
Rebeca Garcia-Macedo
MCMiguel Cruz
Miguel Cruz

21 March 2013 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
SHSergio Hidalgo-Figueroa
Sergio Hidalgo-Figueroa
JRJuan J. Ramírez‐Espinosa
Juan J. Ramírez‐Espinosa
SESamuel Estrada-Soto
Samuel Estrada-Soto
Julio C Almanza-PerezJulio C Almanza-Perez
Julio C Almanza-Perez
RRRubén Román‐Ramos
Rubén Román‐Ramos
RURubén
Rubén

3 January 2011 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
RRRuben Roman-Ramos
Ruben Roman-Ramos
Julio C Almanza-PerezJulio C Almanza-Perez
Julio C Almanza-Perez
RGRebeca Garcia-Macedo
Rebeca Garcia-Macedo
GBGerardo Blancas-Flores
Gerardo Blancas-Flores
AFAngeles Fortis-Barrera
Angeles Fortis-Barrera
FAFrancisco Alarcon Aguilar
Francisco Alarcon Aguilar
The monosodium glutamate (MSG) neonatal administration in mice provides a model of obesity with impaired glucose tolerance (IGT) and insulin resistance. However, the inflammatory profile of cytokines produced from fat tissue and its relationship to the metabolic dysfunction induced by MSG have not yet been revealed. The aim of this study was to establish the inflammatory profile attributed to MSG by measuring the expression of adipokines in visceral fat and serum of 19‐week‐old mice as well as the peroxisome proliferator‐activated receptors alpha and gamma (PPARα and γ). Some metabolic and biochemical parameters were also quantified. The MSG increased mRNA expression of interleukin‐6 (IL‐6), tumour necrosis factor‐alpha (TNFα), resistin and leptin, but adiponectin did not exhibit any changes. In addition, impaired glucose tolerance, increased levels of insulin, resistin and leptin were observed in serum. Both PPARα and PPARγ were activated in MSG‐induced obese mice, which might explain its inflammatory profile. However, liver transaminases were severely depressed, indicating that MSG may also induce liver injury, contributing to inflammation. The MSG neonatal neuro‐intoxication in mice may thus provide a model of obesity and inflammation characterized by the dual activation of PPARα and PPARγ, which might offer new insights into the mechanism of inflammatory diabetes in obesity leading to steatohepatitis, as well as a suitable model to study the role of new therapeutic agents to prevent or reduce insulin resistance, the inflammatory state and liver steatosis.